What is a tumor board and should my Pancreatic Cancer case be reviewed by one

Pancreatic CancerMay 15, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Understanding Tumor Boards for Pancreatic Cancer

What Is a Tumor Board?

A tumor board is a meeting where a team of cancer experts from different specialties comes together to review your individual case and recommend the best possible treatment and testing options for you. Think of it as getting multiple expert opinions at the same time, rather than seeing each specialist separately.

According to Let's Win Pancreatic Cancer, the function of a tumor board is simply to get a multidisciplinary review on a particular case. As one expert explains: "So the patient doesn't need to see every medical expert on the team during a one-on-one appointment, but instead receives advice and insight from all of the experts at the same time through board review."

Who Sits on a Tumor Board?

The experts typically include:

  • Oncologists (cancer doctors specializing in gastrointestinal cancers)
  • Surgeons (if surgery might be an option)
  • Pathologists (specialists who examine tissue samples)
  • Radiologists (doctors who interpret imaging scans)
  • Registered dietitian nutritionists
  • Genetic counselors
  • Gastroenterologists
  • Social workers and nurse navigators
  • Radiation oncologists (if radiation therapy is being considered)

Should Your Pancreatic Cancer Case Be Reviewed?

The short answer: Yes, absolutely. Here's why:

The Case for Tumor Board Review

According to Let's Win Pancreatic Cancer, "The type of questions we need expert opinions on and the complexity around the care for our patients is increasing, so patients require a greater level of expertise." Pancreatic cancer is particularly complex because:

  1. It's a rare specialty - Only 71 National Cancer Institute-designated cancer centers exist in the United States, meaning not all patients have access to pancreatic cancer experts
  2. Treatment options are evolving rapidly - What was standard care 6 months ago may be outdated now
  3. Personalized medicine matters - Your tumor's specific genetic mutations (like KRAS, BRCA1/2, PALB2) can determine which treatments work best for YOU
  4. Multiple pathways exist - Different patients benefit from different approaches (surgery, chemotherapy, targeted therapy, immunotherapy, clinical trials)

Real-World Impact

Research from Cancer Commons shows that tumor boards make a measurable difference. In their pancreatic cancer virtual tumor board program:

  • The board provided 523 treatment and diagnostic options across 103 unique pancreatic cancer cases (an average of 5 options per patient)
  • Of 37 patients who started a subsequent treatment, 59% were identified by the Virtual Tumor Board
  • These included FDA-approved treatments, off-label options, and clinical trial opportunities

Two Types of Tumor Boards Available to You

1. Institutional Tumor Boards (At Your Treatment Center)

If you're being treated at a large-volume cancer center, your case may already be reviewed by an internal tumor board. However, according to the sources, about 80% of pancreatic cancer patients aren't treated at high-volume centers, so this option isn't available to everyone.

2. Virtual Tumor Boards (Remote Expert Review)

This is a game-changer for patients not at major academic centers. Virtual tumor boards bring together experts from multiple institutions across the country to review your case.

Cancer Commons offers a free Virtual Tumor Board specifically for pancreatic cancer patients. Here's how it works:

  • All services are free - No cost to you
  • You get a personalized consult with a Ph.D.-level scientist
  • The board reviews your case including your medical history, tumor characteristics, molecular testing results, and treatment goals
  • You receive a detailed report with treatment recommendations and information on how to access them
  • You can involve your current doctor or use the recommendations to get a second opinion

Key Questions to Ask Your Oncologist

If you're considering a tumor board review, here are important questions to discuss:

  1. "Has my case been reviewed by a tumor board, and if so, what were the recommendations?"

  2. "Has my tumor been molecularly profiled (genetic testing), and do we have results showing KRAS status, BRCA mutations, or other important markers?"

  3. "Are there clinical trials I might be eligible for based on my tumor's genetic profile?"

  4. "Would a second opinion from a major academic cancer center or virtual tumor board be helpful for my specific situation?"

  5. "What are all my treatment options at each stage of my care, including standard chemotherapy, targeted therapy, immunotherapy, and clinical trials?"


Bottom Line

Your pancreatic cancer case should be reviewed by a tumor board. The National Comprehensive Cancer Network (NCCN) recommends a multidisciplinary approach to pancreatic cancer care, and tumor boards are the best way to ensure you're getting the most current, personalized recommendations.

If your current treatment center doesn't have a tumor board review process, or if you want additional expert input, Cancer Commons' free Virtual Tumor Board for pancreatic cancer is an excellent resource. According to the sources, patients have reported learning more from a virtual tumor board in a few weeks than they had in years of treatment.

As one expert notes: "For patients who hear, 'there's nothing more we can do,' a virtual tumor board may open up new options."


This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: